FinCanna Capital Corp. (“FinCanna”) (CSE:CALI), is pleased to report a significant development in the extraction business of its flagship investment in California.
Cultivation Technologies Inc (“CTI”) has announced that it is now directly operating its interim medical cannabis extraction facility (“Interim Extraction Facility”) and plans to directly operate its permanent facility (“Permanent Extraction Facility”) to be constructed at its 6-acre site in Coachella, California.  This change was made possible due to the new regulations in California that took effect on January 1st of this year.  In conjunction with this restructuring, FinCanna and CTI have amended their funding agreement and can capitalize on these significant economic opportunities.
Interim Extraction Facility
The Interim Extraction Facility, which commenced operations in October 2017, had been operated by a third-party tenant of CTI on its site in Coachella.  Under this prior arrangement, CTI was entitled to a maximum of 20% of the production capacity of the Interim Extraction Facility, with at least 80% of production capacity belonging to this third-party tenant, on which CTI was entitled to a minor profit share.  CTI has assumed the operational role and obtained state licenses for Type 7 manufacturing and distribution, and has the rights to 100% of the production capacity, which it will allocate towards extraction services, including white labeling for other brands, and CTI-branded sales.  The new operating structure is expected to result in significant economic opportunities to CTI.  FinCanna continues to be entitled to receive 50% of the profits of CTI which are derived from this Interim Extraction Facility.
This Interim Extraction Facility can currently process an estimated 6,000 pounds of biomass per month to produce approximately 3.7 million grams of raw oil per year.   Under the new operating arrangement, CTI has the ability to add an additional extraction machine and fractional distillation and winterization equipment.  This would result in additional capacity to process 3,000 pounds of biomass per month and the ability to service third-party vaporizer, winterization and distillation customers at a scale of approximately 100,000 grams of finished product weekly.
Permanent Extraction Facility
The Permanent Extraction Facility was planned to be operated by a third-party tenant under similar operating and economic terms as those initially contemplated for the Interim Extraction Facility.  The new arrangement provides CTI with the ability to drive new products lines, add distribution services and improve control over sales channels.  The economics of this new operating arrangement result in potential revenues to CTI that are significantly higher than those expected prior to the restructuring.  As FinCanna receives a royalty based on sales, this translates to a significant increase in expected royalty revenues to FinCanna from the Permanent Extraction Facility once in operation.
Funding Agreement Changes
CTI and FinCanna have also agreed to amend their funding agreement to provide for certain changes to the terms of FinCanna’s investment:

  • CTI to receive US$3.15 million dollars in tranches under the existing loan agreement with FinCanna.  The funds will be used for the restructured extraction operations, to secure an additional 5MW power commitment at the Coachella site and for working capital purposes. The investment allows CTI to capitalize upon the immediate opportunity in California through extraction, manufacturing, and distribution before construction of the Coachella Project;
  • The annual interest rate on the loan increases from 10% to 20%;
  • 7% of CTI’s revenues will be paid to FinCanna and applied against interest and principal on the loan until it is fully repaid, which may accelerate repayment of FinCanna’s loan;
  • The royalty to be earned by FinCanna on CTI’s Coachella Project increases to 14% of revenues and will be paid as a royalty (previously 10% of revenues to be paid as a dividend);
  • A new conversion feature was added to the loan, which allows FinCanna the option to convert the loan into a percentage (up to 5%) of CTI revenues in perpetuity on projects which FinCanna does not elect to fund;
  • Certain deadlines in the funding agreement related to CTI’s project financing for the Coachella Project were extended.

FinCanna CEO, Andriyko Herchak, comments, “We are thrilled with the new operating structure of CTI’s extraction operations.  As revenues from the extraction and manufacturing business are now expected to be the largest segment of CTI’s Coachella Campus, the increase in expected royalties to FinCanna are very significant.  We continue to be impressed by CTI’s exceptional management team and support their strategic approach to the market.”
About Cultivation Technologies
Cultivation Technologies, Inc. provides infrastructure, technology, and branding to the licensed medical cannabis industry. The first major project for the company is in Coachella, California, which will span 6-acres featuring cultivation centers, extraction and manufacturing facilities, a testing lab, a distribution hub, and a centralized processing center. For more information, visit
About FinCanna Capital Corp.
FinCanna is a royalty company for the licensed medical cannabis industry, with a focus on California. FinCanna, led by a team of finance and industry experts, is building its portfolio of investments in scalable, best-in-class projects. FinCanna’s flagship investment is with Cultivation Technologies Inc. (“CTI”) to provide funding for its fully-entitled, large-scale indoor medical cannabis facility to be developed in Coachella, Southern California. This Coachella Campus will be a state-of-the-art facility that will include cultivation, extraction, manufacturing, testing and distribution. For additional information visit
FinCanna Capital Corp.
Andriyko Herchak, CEO & Director
Investor Relations:
Arlen Hansen
Kin Communications
Forward-Looking Information
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about FinCanna’s ability to source suitable projects, the development and construction of the Coachella Facility, and the size and success of operations at the Interim Facility and FinCanna’s ability to generate revenues therefrom.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.
Click here to connect with FinCanna Capital Corp. (CSE:CALI) for an Investor Presentation


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Keep reading... Show less

THC-O-Acetate to be Produced Through Company’s Specialty Molecule Division

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), an extraction company that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has completed construction of an industrial-grade distribution site and launched third party distribution services.

As part of its Phase 1 Construction project at the 196,000 square foot facility, the Company has built out 16,000 square feet of retail-ready product storage space, installed automated, assembly-line style packaging equipment for jar and pouch production, and built out a climate-controlled area that can store 30 tractor-trailer loads of cannabis and 230 pallets positions of -40 degree Fahrenheit freezers for storing live resin and live resin products. A secure loading bay and a small in-house fleet of refrigerated trucks is also in place.

Keep reading... Show less

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“GWS” or the “Company”) is pleased to provide the following corporate update highlights on two portfolio clients KaleidoMyco LLC and Biominerales Pharma Corp. and announces the signing of the one-stop digital marketing team of North Equities Corp.

“With the talent, skills and resources we have at Global Wellness, we are well positioned to develop leading nutraceutical product portfolio brands focused on health and well-being. As hemp-extract and psilocybin is legalized in more jurisdictions such as Oregon where we already have a strong strategic relationship, we can then easily extend our existing product range, which will already have established routes to market and brand recognition, to include myco-dosing products. KaleidoMyco products will be in stores and on a consumer digital platform in the USA shortly and is currently being consumer tested in Europe as well. Our shareholders and customers are extremely important to us and we look forward to meeting the milestones we have outlined with the help of North Equities,” said Meris Kott, CEO.

Keep reading... Show less

VINIA(R)’s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) announces that its flagship VINIA® product is the only dietary supplement available in the US market which has the capability for both reducing the endothelin 1 (ET1) enzyme as well as increasing the nitric oxide (NO) molecules, in order to increase the dilation of arteries and thereby improve blood flow. The presence of ET1 constricts the blood vessel, whereas the presence of NO dilates it. As a result of its “double-action” effect (proven by the Flow Mediated Dilatation (FMD) measurements in a double-blinded Placebo-controlled clinical trial*and in an in-vitro study** whose results were both published), VINIA® is uniquely positioned to combat the aging process caused by a reduction in blood flow.

Keep reading... Show less